140 related articles for article (PubMed ID: 18259973)
1. Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease.
Criner GJ; Sharafkhaneh A; Player R; Conoscenti CS; Johnson P; Keyser MT; Cassino C
COPD; 2008 Feb; 5(1):35-41. PubMed ID: 18259973
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
3. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
Keating GM
Drugs; 2012 Jan; 72(2):273-300. PubMed ID: 22217233
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
5. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Casaburi R; Mahler DA; Jones PW; Wanner A; San PG; ZuWallack RL; Menjoge SS; Serby CW; Witek T
Eur Respir J; 2002 Feb; 19(2):217-24. PubMed ID: 11866001
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group.
van Noord JA; Bantje TA; Eland ME; Korducki L; Cornelissen PJ
Thorax; 2000 Apr; 55(4):289-94. PubMed ID: 10722768
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
8. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
9. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
Casaburi R; Briggs DD; Donohue JF; Serby CW; Menjoge SS; Witek TJ
Chest; 2000 Nov; 118(5):1294-302. PubMed ID: 11083677
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.
Chan CK; Maltais F; Sigouin C; Haddon JM; Ford GT;
Can Respir J; 2007; 14(8):465-72. PubMed ID: 18060091
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.
Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of tiotropium in patients with COPD.
Celli B; Decramer M; Leimer I; Vogel U; Kesten S; Tashkin DP
Chest; 2010 Jan; 137(1):20-30. PubMed ID: 19592475
[TBL] [Abstract][Full Text] [Related]
14. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
15. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
[TBL] [Abstract][Full Text] [Related]
16. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.
Calverley PM; Lee A; Towse L; van Noord J; Witek TJ; Kelsen S
Thorax; 2003 Oct; 58(10):855-60. PubMed ID: 14514937
[TBL] [Abstract][Full Text] [Related]
17. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
Bateman ED; Tashkin D; Siafakas N; Dahl R; Towse L; Massey D; Pavia D; Zhong NS
Respir Med; 2010 Oct; 104(10):1460-72. PubMed ID: 20620037
[TBL] [Abstract][Full Text] [Related]
18. Inhaled tiotropium for stable chronic obstructive pulmonary disease.
Barr RG; Bourbeau J; Camargo CA; Ram FS
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002876. PubMed ID: 15846642
[TBL] [Abstract][Full Text] [Related]
19. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]